Skip to main content
SpringerLink
Log in

A myriad of adverse effects are possible with the long-term use of antiepileptic drugs

  • Drug Reactions and Interactions
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

A large range of adverse effects have been reported in patients receiving long-term antiepileptic drugs (AEDs). These chronic and delayed adverse effects are generally less well known than those that occur early in the course of treatment. Current evidence do not support a definite association between AEDs and cancer, sudden unexplained death or thyroid dysfunction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gaitatzis A, Sander JW. The long-term safety of antiepileptic drugs. CNS Drugs. 2013;27(6):435–55.

    Article  CAS  PubMed  Google Scholar 

  2. Guerrini R, Zaccara G, la Marca G, et al. Safety and tolerability of antiepileptic drug treatment in children with epilepsy. Drug Saf. 2012;35(7):519–33.

    Article  CAS  PubMed  Google Scholar 

  3. Singh G, Driever PH, Sander JW. Cancer risk in people with epilepsy: the role of antiepileptic drugs. Brain. 2005;128(Pt 1):7–17.

    PubMed  Google Scholar 

  4. Hesdorffer DC, Tomson T, Benn E, et al. Do antiepileptic drugs or generalized tonic-clonic seizure frequency increase SUDEP risk? A combined analysis. ILAE Commission on Epidemiology (Subcommission on Mortality). Epilepsia. 2012;53(2):249–52.

    Article  PubMed  Google Scholar 

  5. Ryvlin P, Cucherat M, Rheims S. Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials. Lancet Neurol. 2011;10(11):961–8.

    Article  PubMed  Google Scholar 

  6. Pennell PB. Hormonal aspects of epilepsy. Neurol Clin. 2009;27(4):941–65.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Perucca E, Beghi E, Dulac O, et al. Assessing risk to benefit ratio in antiepileptic drug therapy. Epilepsy Res. 2000;41(2):107–39.

    Article  CAS  PubMed  Google Scholar 

  8. Uijl SG, Uiterwaal CS, Aldenkamp AP, et al. Adjustment of treatment increases quality of life in patients with epilepsy: a randomized controlled pragmatic trial. Eur J Neurol. 2009;16(11):1173–7.

    Article  CAS  PubMed  Google Scholar 

  9. Mattson RH, Cramer JA, McCutchen CB. Barbiturate-related connective tissue disorders. Arch Intern Med. 1989;149(4):911–4.

    Article  CAS  PubMed  Google Scholar 

  10. Mikkonen K, Vainionpää LK, Pakarinen AJ, et al. Long-term reproductive endocrine health in young women with epilepsy during puberty. Neurology. 2004;62(3):445–50.

    Article  CAS  PubMed  Google Scholar 

  11. Isojärvi J. Disorders of reproduction in patients with epilepsy: antiepileptic drug related mechanisms. Seizure. 2008;17(2):111–9.

    Article  PubMed  Google Scholar 

  12. Gough H, Goggin T, Bissessar A, et al. A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in out-patients with epilepsy. Q J Med. 1986;59(230):569–77.

    CAS  PubMed  Google Scholar 

  13. Mintzer S. Metabolic consequences of antiepileptic drugs. Curr Opin Neurol. 2010;23(2):164–9.

    Article  CAS  PubMed  Google Scholar 

  14. Belcastro V, Striano P. Antiepileptic drugs, hyperhomocysteinemia and B-vitamins supplementation in patients with epilepsy. Epilepsy Res. 2012;102(1–2):1–7.

    Article  CAS  PubMed  Google Scholar 

  15. Brickel N, Gandhi P, VanLandingham K, et al. The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels. Epilepsia. 2012;53(4):606–12.

    Article  CAS  PubMed  Google Scholar 

  16. Pellock JM, Wilder BJ, Deaton R, et al. Acute pancreatitis coincident with valproate use: a critical review. Epilepsia. 2002;43(11):1421–4.

    Article  PubMed  Google Scholar 

  17. Saetre E, Abdelnoor M, Amlie JP, et al. Cardiac function and antiepileptic drug treatment in the elderly: a comparison between lamotrigine and sustained-release carbamazepine. Epilepsia. 2009;50(8):1841–9.

    Article  CAS  PubMed  Google Scholar 

  18. Plant GT, Sergott RC. Understanding and interpreting vision safety issues with vigabatrin therapy. Acta Neurol Scand Suppl. 2011;192:57–71.

    Article  PubMed  Google Scholar 

  19. Luef G, Chemelli A, Birbamer G, et al. Phenytoin overdosage and cerebellar atrophy in epileptic patients: clinical and MRI findings. Eur Neurol. 1994;34(Suppl 1):79–81.

    Article  PubMed  Google Scholar 

  20. Zadikoff C, Munhoz RP, Asante AN, et al. Movement disorders in patients taking anticonvulsants. J Neurol Neurosurg Psychiatry. 2007;78(2):147–51.

    Article  CAS  PubMed  Google Scholar 

  21. Wheless JW, Carmant L, Bebin M, et al. Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. Epilepsia. 2009;50(2):195–205.

    Article  CAS  PubMed  Google Scholar 

  22. Eddy CM, Rickards HE, Cavanna AE. The cognitive impact of antiepileptic drugs. Ther Adv Neurol Disord. 2011;4(6):385–407.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Beyenburg S, Mitchell AJ, Schmidt D, et al. Anxiety in patients with epilepsy: systematic review and suggestions for clinical management. Epilepsy Behav. 2005;7(2):161–71.

    Article  PubMed  Google Scholar 

  24. Mula M, Kanner AM, Schmitz B, et al. Antiepileptic drugs and suicidality: an expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology. Epilepsia. 2013;54(1):199–203.

    Article  CAS  PubMed  Google Scholar 

  25. Harden CL, Meador KJ, Pennell PB, et al. Management issues for women with epilepsy: focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 2009;50(5):1237–47.

    Article  PubMed  Google Scholar 

Download references

Disclosure

This article was adapted from CNS Drugs 2013;27(6):435–55 [1]. The preparation of this article was not supported by any external funding; the original review [1] was partly undertaken at the University College Hospitals/University College London, which received funding from the UK’s Department of Health’s National Institute for Health Research Biomedical Research Centres funding scheme.

Author information

Authors and Affiliations

    Consortia

    Adis Medical Writers

    Rights and permissions

    Reprints and permissions

    About this article

    Cite this article

    Adis Medical Writers. A myriad of adverse effects are possible with the long-term use of antiepileptic drugs. Drugs Ther Perspect 30, 105–111 (2014). https://doi.org/10.1007/s40267-013-0084-2

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40267-013-0084-2

    Keywords

    Search

    Navigation